Barchart.com
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Menu
alerts false
Stocks | Futures | Watchlist | News | More
 
Advanced search
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Sutro Biopharma Inc (STRO)

Sutro Biopharma Inc (STRO)
1.3000 x 2 1.3100 x 2
Post-market by (Cboe BZX)
1.3000 +0.4000 (+44.44%) 04/24/25 [NASDAQ]
1.3000 x 2 1.3100 x 2
Post-market 1.3000 unch (unch) 16:50 ET
News & Headlines for Thu, Apr 24th, 2025
Notes
Alerts
Watch
    Add or delete the symbol from one or more Watchlists.
  • Create New Watchlist
    This name already in use.
Help
Go To:
Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025 GlobeNewswire - Sat Mar 15, 5:40PM CDT

STRO : 1.3000 (+44.44%)
Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights GlobeNewswire - Thu Mar 13, 3:07PM CDT

STRO : 1.3000 (+44.44%)
Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline GlobeNewswire - Thu Mar 13, 3:05PM CDT

STRO : 1.3000 (+44.44%)
Sutro Biopharma to Present at the TD Cowen 45th Annual Health Care Conference GlobeNewswire - Mon Mar 3, 3:05PM CST

STRO : 1.3000 (+44.44%)
Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference  GlobeNewswire - Tue Jan 7, 3:05PM CST

STRO : 1.3000 (+44.44%)
Sutro Biopharma and Boehringer Ingelheim BioXcellenceâ„¢ collaboration: Established first-in-class cell-free capabilities at commercial scale GlobeNewswire - Tue Jan 7, 8:00AM CST

STRO : 1.3000 (+44.44%)
Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFRαME-O1 Trial in Platinum Resistant Ovarian Cancer GlobeNewswire - Tue Dec 10, 2024

STRO : 1.3000 (+44.44%)
Sutro Biopharma Reports Third Quarter 2024 Financial Results and Progress on IND Applications and Clinical Trials Quiver Quantitative, Inc. - Thu Nov 14, 2024

Sutro Biopharma reports significant advancements in ADC technology, ongoing trials, and robust financial resources.Quiver AI SummarySutro Biopharma, Inc. announced in its third-quarter 2024 financial results...

STRO : 1.3000 (+44.44%)
Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights GlobeNewswire - Wed Nov 13, 2024

STRO : 1.3000 (+44.44%)
Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference GlobeNewswire - Mon Nov 4, 2024

STRO : 1.3000 (+44.44%)

Barchart Exclusives

Can Grain and Oilseed Prices Higher? Barchart - Thu Apr 24, 2:00PM CDT
While corn, soybean, and wheat prices are higher than their most recent lows, they remain significantly lower than the 2022 high. As the agricultural commodities that feed and increasingly fuel the world are at the beginning of the 2025 crop year, the weather and other issues will determine the path of least resistance of prices. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective
Wed, Apr 30, 2025 5:00 PM UTC
Reserve Your Spot